McCarthy, Philip L. https://orcid.org/0000-0002-9577-3879
Attwood, Kristopher M.
Liu, Xiaojun
Chen, George L.
Minderman, Hans
Alousi, Amin https://orcid.org/0000-0002-2498-8573
Bashey, Asad
Lowsky, Robert
Miklos, David B. https://orcid.org/0000-0003-0717-4305
Hansen, John
Westervelt, Peter
Yanik, Gregory
Waller, Edmund K.
Howard, Alan
Blazar, Bruce R.
Wallace, Paul K.
Reshef, Ran https://orcid.org/0000-0003-2185-9546
Horowitz, Mary M.
Maziarz, Richard T. https://orcid.org/0000-0002-8184-7099
Levine, John E. https://orcid.org/0000-0002-5611-7828
Mohammadpour, Hemn https://orcid.org/0000-0002-0158-7283
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R00HL155792, K99HL155792, U10HL069294, U24HL138660)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Article History
Received: 21 August 2023
Revised: 20 November 2023
Accepted: 29 November 2023
First Online: 18 December 2023
Competing interests
: P.L.M. Advisory Board/Consulting: BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, Takeda; Honoraria: BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, Takeda.